Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
Heinz Gisslinger(Medical University of Vienna), Jiřı́ Schwarz(University Hospital Brno), Róbert Královics(Medical University of Vienna), Lydia Roy(Centre Hospitalier Universitaire de Poitiers), Polina Kaplan, Jean‐Jacques Kiladjian(Délégation Paris 5), Antónia Hatalova, Liana Gercheva(National Institute of Emergency Medicine "Pirogov"), Árpád Illés(University of Debrecen), Sergiy Klymenko, Vera Yablokova, Kurt Krejcy(AOP Orphan (Austria)), Andrei Cucuianu, Dorota Krochmalczyk(Krakow Cardiovascular Research Institute), Ernst Forjan, Miklós Egyed(Somogy Megyei Kaposi Mór Oktató Kórház), Barbara Grohmann-Izay(AOP Orphan (Austria)), O Cerná, Horia Bumbea(Carol Davila University of Medicine and Pharmacy), Richard Greil(Paracelsus Medical University), Halyna Pylypenko(Cherkasy State Technological University), Delia Dima, F. Samuel Bauer, Mario Cazzola(Roche (Switzerland)), Pencho Georgiev(University Multipurpose Hospital for Active Treatment "Sveti Georgi"), Veronika Buxhofer‐Ausch(Johannes Kepler University of Linz), Hans Carl Hasselbalch(Zealand University Hospital), Jiřı́ Mayer(Masaryk University), Zvenyslava Masliak, Alexander Myasnikov, Christoph Klade(Intercell (Austria)), Viktor Rossiev(Samara Regional Clinical Oncology Center), Georgi Mihaylov(Queen Giovanna Hospital), János Jakucs(ELTE Research Centre for the Humanities), Małgorzata Całbecka(Provincial Polyclinical Hospital in Toruń), Petr Ďulíček(University Hospital Hradec Králové), Uwe Platzbecker(National Center for Tumor Diseases), Emilie Cayssials-Caylus, Tamila Lysa, Nicoleta P. Berbec, Tamás Masszi, Mathieu Puyade, Jérôme Rey, Lylia Sivcheva(National Institute of Emergency Medicine "Pirogov"), Mihaela Lazaroiu, M Hrubisko, Zita Borbényi, Carlos Besses Raebel, Emanuil Gheorghita, Steffen Koschmieder(RWTH Aachen University)
Cited by 351
Related Papers
A Gain-of-Function Mutation of <i>JAK2</i> in Myeloproliferative Disorders
|New England Journal of Medicine|2005|3.5k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Clinical and biological implications of driver mutations in myelodysplastic syndromes
|Blood|2013|1.8k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k